| Nr. | Year OPEN | Title | users say | rate good | rate bad | no link | Citation |
|---|
AntisenseAntibiotics (BASKET)SplicingLocked Nucleic AcidRNA (non coding)| 1 | 2004 | 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) as next-generation antisense and antigene agents. | 
| + | - | nl | Biol Pharm Bull 27(4):453-6 (2004) Koizumi M |
| 2 | 1998 | Antisense RNA: function and fate of duplex RNA in cells of higher eukaryotes. |
| + | - | nl | Microbiol Mol Biol Rev 62(4):1415-34 (1998) |
| 3 | 1998 | Gene therapy for infectious diseases. |
| + | - | nl | Clin Microbiol Rev 11(1):42-56 (1998) |
| 4 | 2009 | Improved applications of the tetracycline-regulated gene depletion system. |
| + | - | nl | Biosci Trends 3(5):161-7 (2009) Nishijima H |
| 5 | 2007 | Regulating gene expression with light-activated oligonucleotides. |
| + | - | nl | Mol Biosyst 3(2):100-10 (2007) Tang X |
| 6 | 2008 | Advances in antisense oligonucleotide development for target identification, validation, and as novel therapeutics. |
| + | - | nl | Gene Regul Syst Bio 2():275-95 (2008) Mansoor M |
| 7 | 2008 | DNAzyme technology and cancer therapy: cleave and let die. |
| + | - | nl | Mol Cancer Ther 7(2):243-51 (2008) Dass CR |
| 8 | 2002 | Antisense oligonucleotides: basic concepts and mechanisms. |
| + | - | nl | Mol Cancer Ther 1(5):347-55 (2002) Dias N |
| 9 | 1988 | Oligodeoxynucleotides as inhibitors of gene expression: a review. |
| + | - | nl | Cancer Res 48(10):2659-68 (1988) |
| 10 | 2009 | A renaissance for antisense oligonucleotide drugs in neurology: exon skipping breaks new ground. |
| + | - | nl | Arch Neurol 66(1):32-8 (2009) Yokota T |
| 11 | 2001 | Triplex forming oligonucleotides: sequence-specific tools for gene targeting. |
| + | - | nl | Hum Mol Genet 10(20):2243-51 (2001) |
| 12 | 2000 | Catalytic DNAs as potential therapeutic agents and sequence-specific molecular tools to dissect biological function. |
| + | - | nl | J Clin Invest 106(10):1189-95 (2000) |
| 13 | 2000 | Therapeutic applications of transcription factor decoy oligonucleotides. |
| + | - | nl | J Clin Invest 106(9):1071-5 (2000) |
| 14 | 1997 | Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. |
| + | - | nl | Hepatology 26(2):251-5 (1997) |
| 15 | 1996 | A hitchhiker's guide to antisense and nonantisense biochemical pathways. |
| + | - | nl | Hepatology 24(6):1517-29 (1996) |
| 16 | 1999 | Antisense and nuclear medicine. |
| + | - | nl | J Nucl Med 40(4):693-703 (1999) |
| 17 | 2001 | Prospects of chimeric RNA-DNA oligonucleotides in gene therapy. |
| + | - | nl | J Biomed Sci 8(6):439-45 (2001) |
| 18 | 2003 | Design and applications of modified oligonucleotides. |
| + | - | nl | Braz J Med Biol Res 36(2):143-51 (2003) Gallo M |
| 19 | 2004 | Progress in the development of nucleic acid therapeutics for cancer. |
| + | - | nl | Cancer Biol Ther 3(1):4-12 (2004) |
| 20 | 2011 | Oligonucleotides decoy to NF-kappaB: becoming a reality? |
| + | - | nl | Discov Med 12(63):97-105 (2011) |
| 21 | 2003 | Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. |
| + | - | nl | J Clin Invest 112(4):481-6 (2003) |
| 22 | 2003 | Antisense technologies. Improvement through novel chemical modifications. |
| + | - | nl | Eur J Biochem 270(8):1628-44 (2003) |
| 23 | 2009 | Locked nucleic acid as a novel class of therapeutic agents. |
| + | - | nl | RNA Biol 6(3):321-3 (2009) |
| 24 | 2009 | Regulatory roles of natural antisense transcripts. |
| + | - | nl | Nat Rev Mol Cell Biol 10(9):637-43 (2009) |
